Therapeutic concepts for hypoxic pulmonary vasoconstriction involving ion regulation and the smooth muscle contractile apparatus

Journal of Molecular and Cellular Cardiology

Volumn 40, Issue 6, 2006, Pages 751-760

  Morrell, Eric D ^a   Tsai, Ben M ^a   Crisostomo, Paul R ^a   Wang, Meijing ^a   Markel, Troy A ^a   Lillemoe, Keith D ^a   Meldrum, Daniel R ^a,b  

^a INDIANA UNIVERSITY MEDICAL CENTER   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Calcium (cellular); Hypoxia; K channel; Pulmonary circulation

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 (4 FLUOROPHENYL) 2 (4 HYDROXYPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 4 [(1,6 DIHYDRO 1 METHYL 6 OXO 3 PYRIDAZINYL)AMINO] 3 HYDROXY 2,2 BIS(METHOXYMETHYL)CHROMAN 6 CARBONITRILE; ACETYLCYSTEINE; ADENOVIRUS VECTOR; ANTIOXIDANT; CALCITONIN GENE RELATED PEPTIDE; DICHLOROACETIC ACID; DIMETHYLTHIOUREA; FASUDIL; GLUCOCORTICOID; ION CHANNEL; IPTAKALIM; LEVOSIMENDAN; NITRIC OXIDE; POTASSIUM CHANNEL; POTASSIUM CHANNEL STIMULATING AGENT; PRASTERONE; RHO KINASE; RHO KINASE INHIBITOR; VASODILATOR AGENT;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ABSENCE OF SIDE EFFECTS; ADRENAL INSUFFICIENCY; AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; GENE EXPRESSION; GENE TRANSFER; HEART FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPOTENSION; HYPOXIC LUNG VASOCONSTRICTION; MEDICAL RESEARCH; NONHUMAN; OXIDATION REDUCTION REACTION; PRIORITY JOURNAL; PULMONARY ARTERY DISEASE; PULMONARY HYPERTENSION; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SMOOTH MUSCLE CONTRACTILITY; SURGEON; THIAMINE DEFICIENCY; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

ANOXIA; HUMANS; ION CHANNELS; LUNG; MUSCLE CONTRACTION; MUSCLE, SMOOTH; VASOCONSTRICTION;

HUMAN PAPILLOMAVIRUS;

EID: 33745448412     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2006.03.431     Document Type: Review

References (145)

1. Kato M., and Staub N.C. Response of small pulmonary arteries to unilobar hypoxia and hypercapnia. Circ Res 19 (1966) 426-440
2. Brimioulle S., Julien V., Gust R., Kozlowski J.K., Naeije R., and Schuster D.P. Importance of hypoxic vasoconstriction in maintaining oxygenation during acute lung injury. Crit Care Med 30 (2002) 874-880
3. Brimioulle S., LeJeune P., and Naeije R. Effects of hypoxic pulmonary vasoconstriction on pulmonary gas exchange. J Appl Physiol 81 (1996) 1535-1543
4. Harris P., and Heath D. The human pulmonary circulation (1986), Churchill Livingstone, London
5. Leach R.M., and Treacher D.F. Clinical aspects of hypoxic pulmonary vasoconstriction. Exp Physiol 80 (1995) 865-875
6. Erdmann III A.J., Vaughan Jr. T.R., Brigham K.L., Woolverton W.C., and Staub N.C. Effect of increased vascular pressure on lung fluid balance in unanesthetized sheep. Circ Res 37 (1975) 271-284
7. Sibbald W.J., Driedger A.A., Myers M.L., Short A.I., and Wells G.A. Biventricular function in the adult respiratory distress syndrome. Chest 84 (1983) 126-134
8. Jardin F., Gurdjian F., Delille F., and Margairaz A. Pulmonary hypertension in the adult respiratory distress syndrome (ARDS). Intensive Care Med 5 (1979) 155-156
9. Dawes G.S., Mott J.C., Widdicombe J.G., and Wyatt D.G. Changes in the lungs of the new-born lamb. J Physiol 121 (1953) 141-162
10. 2-sensor in resistance artery smooth muscle cells. J Mol Cell Cardiol 37 (2004) 1119-1136
11. Hopkins R.A., Bull C., Haworth S.G., de Leval M.R., and Stark J. Pulmonary hypertensive crises following surgery for congenital heart defects in young children. Eur J Cardio-thorac Surg 5 (1991) 628-634
12. Kimblad P.O., Green K., Sjoberg T., and Steen S. Prostanoid release after lung transplantation. J Heart Lung Transplant 15 (1996) 999-1004
13. Robin E.D., Theodore J., Burke C.M., Oesterle S.N., Fowler M.B., Jamieson S.W., et al. Hypoxic pulmonary vasoconstriction persists in the human transplanted lung. Clin Sci (Lond) 72 (1987) 283-287
14. Singh I., Khanna P.K., Lal M., Hoon R.S., and Rao B.D. High-altitude pulmonary hypertension. Lancet 19 (1965) 146-150
15. Tsai B.M., Wang M., Turrentine M.W., Mahomed Y., Brown J.W., and Meldrum D.R. Hypoxic pulmonary vasoconstriction in cardiothoracic surgery: basic mechanisms to potential therapies. Ann Thorac Surg 78 (2004) 360-368
16. Weir E.K., and Archer S.L. The mechanism of acute hypoxic pulmonary vasoconstriction: the tale of two channels. FASEB J 9 (1995) 183-189
17. Mauban J.R., Remillard C.V., and Yuan J.X. Hypoxic pulmonary vasoconstriction: role of ion channels. J Appl Physiol 98 (2005) 415-420
18. Hardingham G.E., Chawla S., Johnson C.M., and Bading H. Distinct functions of nuclear and cytoplasmic calcium in the control of gene expression. Nature 385 (1997) 260-265
19. Means A.R. Calcium, calmodulin and cell cycle regulation. FEBS Lett 347 (1994) 1-4
20. Platoshyn O., Golovina V.A., Bailey C.L., Limsuwan A., Krick S., Juhaszova M., et al. Sustained membrane depolarization and pulmonary artery smooth muscle cell proliferation. Am J Physiol, Cell Physiol 279 (2000) C1540-C1549
21. Tsai, BWM, Pitcher, J, Kher, A, Meldrum, D. Disparate IL-1 beta and iNOS gene expression in the aorta and pulmonary artery following endotoxemia. Surg Infect [in press].
22. Tsai B.M., Wang M., Pitcher J.M., Kher A., Brown J.W., and Meldrum D.R. Endothelium-dependent pulmonary artery vasorelaxation is dysfunctional in males but not females after acute lung injury. Surgery 138 (2005) 78-84
23. Johnson A., and Ferro T.J. TNF-alpha augments pulmonary vasoconstriction via the inhibition of nitrovasodilator activity. J Appl Physiol 73 (1992) 2483-2492
24. Kisala J.M., Ayala A., Stephan R.N., and Chaudry I.H. A model of pulmonary atelectasis in rats: activation of alveolar macrophage and cytokine release. Am J Physiol 264 (1993) R610-R614
25. Lindsey H.J., Kisala J.M., Ayala A., Lehman D., Herdon C.D., and Chaudry I.H. Pentoxifylline attenuates oxygen-induced lung injury. J Surg Res 56 (1994) 543-548
26. Stevens T., Janssen P.L., and Tucker A. Acute and long-term TNF-alpha administration increases pulmonary vascular reactivity in isolated rat lungs. J Appl Physiol 73 (1992) 708-712
27. Tsai, BTM, Sheridan, BC, Wang, M, Fiore, AC, Brown, JW, Meldrum, D. Differential effects of phosphodiesterase-5 inhibitors on hypoxic pulmonary vasoconstriction and pulmonary artery cytokine expression. Ann Thorac Surg [in press].
28. Tsai B.M., Wang M., Clauss M., Sun P., and Meldrum D.R. Endothelial monocyte-activating polypeptide II causes NOS-dependent pulmonary artery vasodilation: a novel effect for a proinflammatory cytokine. Am J Physiol, Regul Integr Comp Physiol 287 (2004) R767-R771
29. Tsai B.M., Wang M., March K.L., Turrentine M.W., Brown J.W., and Meldrum D.R. Preconditioning: evolution of basic mechanisms to potential therapeutic strategies. Shock 21 (2004) 195-209
30. Tsai B.M., Wang M., Pitcher J.M., Meldrum K.K., and Meldrum D.R. Hypoxic pulmonary vasoconstriction and pulmonary artery tissue cytokine expression are mediated by protein kinase C. Am J Physiol, Lung Cell Mol Physiol 287 (2004) L1215-L1219
31. Karamsetty M.R., Klinger J.R., and Hill N.S. Evidence for the role of p38 MAP kinase in hypoxia-induced pulmonary vasoconstriction. Am J Physiol, Lung Cell Mol Physiol 283 (2002) L859-L866
32. Ward J.P., Knock G.A., Snetkov V.A., and Aaronson P.I. Protein kinases in vascular smooth muscle tone-Role in the pulmonary vasculature and hypoxic pulmonary vasoconstriction. Pharmacol Ther 104 (2004) 207-231
33. Morrell, E, Tsai, B, Crisostomo, P, Hammoud, Z, Meldrum, D. Experimental therapies for hypoxia-induced pulmonary hypertension during acute lung injury. Shock [in press].
34. Archer S.L., Will J.A., and Weir E.K. Redox status in the control of pulmonary vascular tone. Herz 11 (1986) 127-141
35. 2 sensor in rat pulmonary vasculature. Circ Res 73 (1993) 1100-1112
36. Moudgil R., Michelakis E.D., and Archer S.L. Hypoxic pulmonary vasoconstriction. J Appl Physiol 98 (2005) 390-403
37. 2 radicals and pulmonary vascular reactivity in rat lung. J Appl Physiol 67 (1989) 1903-1911
38. Paky A., Michael J.R., Burke-Wolin T.M., Wolin M.S., and Gurtner G.H. Endogenous production of superoxide by rabbit lungs: effects of hypoxia or metabolic inhibitors. J Appl Physiol 74 (1993) 2868-2874
39. Reeve H.L., Weir E.K., Nelson D.P., Peterson D.A., and Archer S.L. Opposing effects of oxidants and antioxidants on K+ channel activity and tone in rat vascular tissue. Exp Physiol 80 (1995) 825-834
40. Freeman B.A., and Crapo J.D. Hyperoxia increases oxygen radical production in rat lungs and lung mitochondria. J Biol Chem 256 (1981) 10986-10992
41. 2+ channel to beta-adrenergic receptor stimulation in cardiac myocytes. Circ Res 91 (2002) 601-609
42. Reeve H.L., Michelakis E., Nelson D.P., Weir E.K., and Archer S.L. Alterations in a redox oxygen sensing mechanism in chronic hypoxia. J Appl Physiol 90 (2001) 2249-2256
43. 2 sensing is preserved in mice lacking the gp91 phox subunit of NADPH oxidase. Proc Natl Acad Sci USA 96 (1999) 7944-7949
44. Lachmanova V., Hnilickova O., Povysilova V., Hampl V., and Herget J. N-acetylcysteine inhibits hypoxic pulmonary hypertension most effectively in the initial phase of chronic hypoxia. Life Sci 77 (2005) 175-182
45. Lai Y.L., Wu H.D., and Chen C.F. Antioxidants attenuate chronic hypoxic pulmonary hypertension. J Cardiovasc Pharmacol 32 (1998) 714-720
46. Liu J.Q., Sham J.S., Shimoda L.A., Kuppusamy P., and Sylvester J.T. Hypoxic constriction and reactive oxygen species in porcine distal pulmonary arteries. Am J Physiol, Lung Cell Mol Physiol 285 (2003) L322-L333
47. Waypa G.B., Chandel N.S., and Schumacker P.T. Model for hypoxic pulmonary vasoconstriction involving mitochondrial oxygen sensing. Circ Res 88 (2001) 1259-1266
48. Waypa G.B., Marks J.D., Mack M.M., Boriboun C., Mungai P.T., and Schumacker P.T. Mitochondrial reactive oxygen species trigger calcium increases during hypoxia in pulmonary arterial myocytes. Circ Res 91 (2002) 719-726
49. Hoshikawa Y., Ono S., Suzuki S., Tanita T., Chida M., Song C., et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. J Appl Physiol 90 (2001) 1299-1306
50. Archer S., and Michelakis E. The mechanism(s) of hypoxic pulmonary vasoconstriction: potassium channels, redox O(2) sensors, and controversies. News Physiol Sci 17 (2002) 131-137
51. Archer S.L., Souil E., Dinh-Xuan A.T., Schremmer B., Mercier J.C., and El Yaagoubi A. Molecular identification of the role of voltage-gated K+ channels, Kv1.5 and Kv2.1, in hypoxic pulmonary vasoconstriction and control of resting membrane potential in rat pulmonary artery myocytes. J Clin Invest 101 (1998) 2319-2330
52. Hong Z., Weir E.K., Nelson D.P., and Olschewski A. Subacute hypoxia decreases voltage-activated potassium channel expression and function in pulmonary artery myocytes. Am J Respir Cell Mol Biol 31 (2004) 337-343
53. Wang J., Weigand L., Wang W., Sylvester J.T., and Shimoda L.A. Chronic hypoxia inhibits Kv channel gene expression in rat distal pulmonary artery. Am J Physiol, Lung Cell Mol Physiol 288 (2005) L1049-L1058
54. Hasunuma K., Rodman D.M., and McMurtry I.F. Effects of K+ channel blockers on vascular tone in the perfused rat lung. Am Rev Respir Dis 144 (1991) 884-887
55. Post J.M., Gelband C.H., and Hume J.R. [Ca2+]i inhibition of K+ channels in canine pulmonary artery. Novel mechanism for hypoxia-induced membrane depolarization. Circ Res 77 (1995) 131-139
56. Yuan X.J., Tod M.L., Rubin L.J., and Blaustein M.P. Hypoxic and metabolic regulation of voltage-gated K+ channels in rat pulmonary artery smooth muscle cells. Exp Physiol 80 (1995) 803-813
57. Archer S.L., London B., Hampl V., Wu X., Nsair A., Puttagunta L., et al. Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. FASEB J 15 (2001) 1801-1803
58. 2-sensitive K+ channels in resistance pulmonary arteries explains regional heterogeneity in hypoxic pulmonary vasoconstriction: ionic diversity in smooth muscle cells. Circ Res 95 (2004) 308-318
59. Sakai M., Unemoto K., Solari V., and Puri P. Decreased expression of voltage-gated K+ channels in pulmonary artery smooth muscles cells in nitrofen-induced congenital diaphragmatic hernia in rats. Pediatr Surg Int 20 (2004) 192-196
60. Platoshyn O., Yu Y., Golovina V.A., McDaniel S.S., Krick S., Li L., et al. Chronic hypoxia decreases K(V) channel expression and function in pulmonary artery myocytes. Am J Physiol, Lung Cell Mol Physiol 280 (2001) L801-L812
61. Post J.M., Hume J.R., Archer S.L., and Weir E.K. Direct role for potassium channel inhibition in hypoxic pulmonary vasoconstriction. Am J Physiol 262 (1992) C882-C890
62. Yuan X.J., Goldman W.F., Tod M.L., Rubin L.J., and Blaustein M.P. Hypoxia reduces potassium currents in cultured rat pulmonary but not mesenteric arterial myocytes. Am J Physiol 264 (1993) L116-L123
63. Stacpoole P.W., Harman E.M., Curry S.H., Baumgartner T.G., and Misbin R.I. Treatment of lactic acidosis with dichloroacetate. N Engl J Med 309 (1983) 390-396
64. Stacpoole P.W., Wright E.C., Baumgartner T.G., Bersin R.M., Buchalter S., Curry S.H., et al., The Dichloroacetate-Lactic Acidosis Study Group. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. N Engl J Med 327 (1992) 1564-1569
65. Rozanski G.J., Xu Z., Zhang K., and Patel K.P. Altered K+ current of ventricular myocytes in rats with chronic myocardial infarction. Am J Physiol 274 (1998) H259-H265
66. Michelakis E.D., McMurtry M.S., Wu X.C., Dyck J.R., Moudgil R., Hopkins T.A., et al. Dichloroacetate, a metabolic modulator, prevents and reverses chronic hypoxic pulmonary hypertension in rats: role of increased expression and activity of voltage-gated potassium channels. Circulation 105 (2002) 244-250
67. Dallaporta B., Hirsch T., Susin S.A., Zamzami N., Larochette N., Brenner C., et al. Potassium leakage during the apoptotic degradation phase. J Immunol 160 (1998) 5605-5615
68. Mandegar M., Remillard C.V., and Yuan J.X. Ion channels in pulmonary arterial hypertension. Prog Cardiovasc Dis 45 (2002) 81-114
69. McMurtry M.S., Bonnet S., Wu X., Dyck J.R., Haromy A., Hashimoto K., et al. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ Res 95 (2004) 830-840
70. Stacpoole P.W. The pharmacology of dichloroacetate. Metabolism 38 (1989) 1124-1144
71. Stacpoole P.W., Nagaraja N.V., and Hutson A.D. Efficacy of dichloroacetate as a lactate-lowering drug. J Clin Pharmacol 43 (2003) 683-691
72. Nelson M.T., and Quayle J.M. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 268 (1995) C799-C822
73. Xie W., Wang H., Wang H., and Hu G. Effects of iptakalim hydrochloride, a novel KATP channel opener, on pulmonary vascular remodeling in hypoxic rats. Life Sci 75 (2004) 2065-2076
74. Tsutsumi Y., Makita T., Yamaguchi K., Shibata O., and Sumikawa K. JTV-506, a new K(ATP) channel opener, relaxes pulmonary artery isolated from monocrotaline-treated pulmonary hypertensive rats. J Anesth 18 (2004) 210-215
75. Brayden J.E., and Nelson M.T. Regulation of arterial tone by activation of calcium-dependent potassium channels. Science 256 (1992) 532-535
76. Gebremedhin D., Bonnet P., Greene A.S., England S.K., Rusch N.J., Lombard J.H., et al. Hypoxia increases the activity of Ca(2+)-sensitive K+ channels in cat cerebral arterial muscle cell membranes. Pflugers Arch 428 (1994) 621-630
77. Peng W., Hoidal J.R., Karwande S.V., and Farrukh I.S. Effect of chronic hypoxia on K+ channels: regulation in human pulmonary vascular smooth muscle cells. Am J Physiol 272 (1997) C1271-C1278
78. Bonnet S., Dumas-de-La-Roque E., Begueret H., Marthan R., Fayon M., Dos Santos P., et al. Dehydroepiandrosterone (DHEA) prevents and reverses chronic hypoxic pulmonary hypertension. Proc Natl Acad Sci USA 100 (2003) 9488-9493
79. Hampl V., Bibova J., Povysilova V., and Herget J. Dehydroepiandrosterone sulphate reduces chronic hypoxic pulmonary hypertension in rats. Eur Respir J 21 (2003) 862-865
80. Arlt W., Callies F., van Vlijmen J.C., Koehler I., Reincke M., Bidlingmaier M., et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 341 (1999) 1013-1020
81. Baulieu E.E., Thomas G., Legrain S., Lahlou N., Roger M., Debuire B., et al. Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: contribution of the DHEAge Study to a sociobiomedical issue. Proc Natl Acad Sci USA 97 (2000) 4279-4284
82. Jesse R.L., Loesser K., Eich D.M., Qian Y.Z., Hess M.L., and Nestler J.E. Dehydroepiandrosterone inhibits human platelet aggregation in vitro and in vivo. Ann NY Acad Sci 774 (1995) 281-290
83. Yokoshiki H., Katsube Y., Sunagawa M., and Sperelakis N. The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 283 (1997) 375-383
84. Oldner A., Konrad D., Weitzberg E., Rudehill A., Rossi P., and Wanecek M. Effects of levosimendan, a novel inotropic calcium-sensitizing drug, in experimental septic shock. Crit Care Med 29 (2001) 2185-2193
85. Schulze-Neick I., Luther Y.C., Ewert P., Lehmkuhl H.B., Hetzer R., and Lange P.E. End-stage heart failure with pulmonary hypertension: levosimendan to evaluate for heart transplantation alone versus combined heart-lung transplantation. Transplantation 78 (2004) 1237-1238
86. Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs 14 (2005) 659-670
87. Lehtonen L. Levosimendan: a calcium-sensitizing agent for the treatment of patients with decompensated heart failure. Curr Heart Fail Rep 1 (2004) 136-144
88. Dumas J.P., Bardou M., Goirand F., and Dumas M. Hypoxic pulmonary vasoconstriction. Gen Pharmacol 33 (1999) 289-297
89. Pollesello P., and Mebazaa A. ATP-dependent potassium channels as a key target for the treatment of myocardial and vascular dysfunction. Curr Opin Crit Care 10 (2004) 436-441
90. 2-sensitive potassium channel Kv1.5 reduces pulmonary hypertension and restores hypoxic pulmonary vasoconstriction in chronically hypoxic rats. Circulation 107 (2003) 2037-2044
91. Michelakis E.D., Dyck J.R., McMurtry M.S., Wang S., Wu X.C., Moudgil R., et al. Gene transfer and metabolic modulators as new therapies for pulmonary hypertension. Increasing expression and activity of potassium channels in rat and human models. Adv Exp Med Biol 502 (2001) 401-418
92. Champion H.C., Bivalacqua T.J., Toyoda K., Heistad D.D., Hyman A.L., and Kadowitz P.J. In vivo gene transfer of prepro-calcitonin gene-related peptide to the lung attenuates chronic hypoxia-induced pulmonary hypertension in the mouse. Circulation 101 (2000) 923-930
93. Nelson M.T., Huang Y., Brayden J.E., Hescheler J., and Standen N.B. Arterial dilations in response to calcitonin gene-related peptide involve activation of K+ channels. Nature 344 (1990) 770-773
94. Mannan M.M., Springall D.R., Enard C., Moradoghli-Haftvani A., Eddahibi S., Adnot S., et al. Decreased endothelium-dependent pulmonary vasodilator effect of calcitonin gene-related peptide in hypoxic rats contrasts with increased binding sites. Eur Respir J 8 (1995) 2029-2037
95. 2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G proteins, kinases, and myosin phosphatase. Physiol Rev 83 (2003) 1325-1358
96. Nishimura J., Khalil R.A., and van Breemen C. Agonist-induced vascular tone. Hypertension 13 (1989) 835-844
97. Wettschureck N., and Offermanns S. Rho/Rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med 80 (2002) 629-638
98. Aaronson P.I., Robertson T.P., and Ward J.P. Endothelium-derived mediators and hypoxic pulmonary vasoconstriction. Respir Physiol Neurobiol 132 (2002) 107-120
99. Archer S.L., Tolins J.P., Raij L., and Weir E.K. Hypoxic pulmonary vasoconstriction is enhanced by inhibition of the synthesis of an endothelium derived relaxing factor. Biochem Biophys Res Commun 164 (1989) 1198-1205
100. 2+ sensitization during sustained hypoxic pulmonary vasoconstriction is endothelium dependent. Am J Physiol, Lung Cell Mol Physiol 284 (2003) L1121-L1126
101. Xu J., and Liu L. The role of calcium desensitization in vascular hyporeactivity and its regulation after hemorrhagic shock in the rat. Shock 23 (2005) 576-581
102. Uehata M., Ishizaki T., Satoh H., Ono T., Kawahara T., Morishita T., et al. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 389 (1997) 990-994
103. Abe K., Shimokawa H., Morikawa K., Uwatoku T., Oi K., Matsumoto Y., et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94 (2004) 385-393
104. Hyvelin J.M., Howell K., Nichol A., Costello C.M., Preston R.J., and McLoughlin P. Inhibition of Rho-kinase attenuates hypoxia-induced angiogenesis in the pulmonary circulation. Circ Res 97 (2005) 185-191
105. Laufs U., Marra D., Node K., and Liao J.K. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27 (Kip1). J Biol Chem 274 (1999) 21926-21931
106. Horton J.W., Maass D.L., and Ballard-Croft C. Rho-associated kinase modulates myocardial inflammatory cytokine responses. Shock 24 (2005) 53-58
107. Castaneda J., Isusi A., and Tamayo L. Hypoxic pulmonary vasoconstriction increases during endotoxemia in the perfused rat lung. J Trauma 50 (2001) 882-886
108. Liu S.F., Dewar A., Crawley D.E., Barnes P.J., and Evans T.W. Effect of tumor necrosis factor on hypoxic pulmonary vasoconstriction. J Appl Physiol 72 (1992) 1044-1049
109. Ertel W., Morrison M.H., Ayala A., and Chaudry I.H. Hypoxemia in the absence of blood loss or significant hypotension causes inflammatory cytokine release. Am J Physiol 269 (1995) R160-R166
110. Fagan K.A., Oka M., Bauer N.R., Gebb S.A., Ivy D.D., Morris K.G., et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol, Lung Cell Mol Physiol 287 (2004) L656-L664
111. Nagaoka T., Fagan K.A., Gebb S.A., Morris K.G., Suzuki T., Shimokawa H., et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 171 (2005) 494-499
112. Nagaoka T., Morio Y., Casanova N., Bauer N., Gebb S., McMurtry I., et al. Rho/Rho kinase signaling mediates increased basal pulmonary vascular tone in chronically hypoxic rats. Am J Physiol, Lung Cell Mol Physiol 287 (2004) L665-L672
113. Robertson T.P., Dipp M., Ward J.P., Aaronson P.I., and Evans A.M. Inhibition of sustained hypoxic vasoconstriction by Y-27632 in isolated intrapulmonary arteries and perfused lung of the rat. Br J Pharmacol 131 (2000) 5-9
114. Gutjahr M.C., Rossy J., and Niggli V. Role of Rho, Rac, and Rho-kinase in phosphorylation of myosin light chain, development of polarity, and spontaneous migration of Walker 256 carcinosarcoma cells. Exp Cell Res 308 (2005) 422-438
115. Szaszi K., Sirokmany G., Di Ciano-Oliveira C., Rotstein O.D., and Kapus A. Depolarization induces Rho-Rho kinase-mediated myosin light chain phosphorylation in kidney tubular cells. Am J Physiol, Cell Physiol 289 (2005) C673-C685
116. Chiba Y., Takeyama H., Sakai H., and Misawa M. Effects of Y-27632 on acetylcholine-induced contraction of intact and permeabilized intrapulmonary bronchial smooth muscles in rats. Eur J Pharmacol 427 (2001) 77-82
117. Iizuka K., Shimizu Y., Tsukagoshi H., Yoshii A., Harada T., Dobashi K., et al. Evaluation of Y-27632, a rho-kinase inhibitor, as a bronchodilator in guinea pigs. Eur J Pharmacol 406 (2000) 273-279
118. Nakahara T., Moriuchi H., Yunoki M., Sakamato K., and Ishii K. Y-27632 potentiates relaxant effects of beta 2-adrenoceptor agonists in bovine tracheal smooth muscle. Eur J Pharmacol 389 (2000) 103-106
119. Tokuyama K., Nishimura H., Iizuka K., Kato M., Arakawa H., Saga R., et al. Effects of Y-27632, a Rho/Rho kinase inhibitor, on leukotriene D(4)- and histamine-induced airflow obstruction and airway microvascular leakage in guinea pigs in vivo. Pharmacology 64 (2002) 189-195
120. Hall A. Rho GTPases and the actin cytoskeleton. Science 279 (1998) 509-514
121. Narumiya S. The small GTPase Rho: cellular functions and signal transduction. J Biochem (Tokyo) 120 (1996) 215-228
122. Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol 39 (2002) 319-327
123. Masumoto A., Mohri M., Shimokawa H., Urakami L., Usui M., and Takeshita A. Suppression of coronary artery spasm by the Rho-kinase inhibitor fasudil in patients with vasospastic angina. Circulation 105 (2002) 1545-1547
124. Fukumoto Y., Matoba T., Ito A., Tanaka H., Kishi T., Hayashidani S., et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91 (2005) 391-392
125. Galaria I.I., Fegley A.J., Nicholl S.M., Roztocil E., and Davies M.G. Differential regulation of ERK1/2 and p38 (MAPK) by components of the Rho signaling pathway during sphingosine-1-phosphate-induced smooth muscle cell migration. J Surg Res 122 (2004) 173-179
126. Lopez-Ilasaca M. Signaling from G-protein-coupled receptors to mitogen-activated protein (MAP)-kinase cascades. Biochem Pharmacol 56 (1998) 269-277
127. Nwariaku F.E., Rothenbach P., Liu Z., Zhu X., Turnage R.H., and Terada L.S. Rho inhibition decreases TNF-induced endothelial MAPK activation and monolayer permeability. J Appl Physiol 95 (2003) 1889-1895
128. Guay J., Lambert H., Gingras-Breton G., Lavoie J.N., Huot J., and Landry J. Regulation of actin filament dynamics by p38 map kinase-mediated phosphorylation of heat shock protein 27. J Cell Sci 110 Pt 3 (1997) 357-368
129. Larsen J.K., Yamboliev I.A., Weber L.A., and Gerthoffer W.T. Phosphorylation of the 27-kDa heat shock protein via p38 MAP kinase and MAPKAP kinase in smooth muscle. Am J Physiol 273 (1997) L930-L940
130. Yamboliev I.A., Hedges J.C., Mutnick J.L., Adam L.P., and Gerthoffer W.T. Evidence for modulation of smooth muscle force by the p38 MAP kinase/HSP27 pathway. Am J Physiol, Heart Circ Physiol 278 (2000) H1899-H1907
131. Gerthoffer W.T., and Gunst S.J. Invited review: focal adhesion and small heat shock proteins in the regulation of actin remodeling and contractility in smooth muscle. J Appl Physiol 91 (2001) 963-972
132. Jin N., Hatton N., Swartz D.R., Xia X., Harrington M.A., Larsen S.H., et al. Hypoxia activates jun-N-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol 23 (2000) 593-601
133. Wang M., Sankula R., Tsai B.M., Meldrum K.K., Turrentine M., March K.L., et al. P38 MAPK mediates myocardial proinflammatory cytokine production and endotoxin-induced contractile suppression. Shock 21 (2004) 170-174
134. Kita T., Yamaguchi H., Sato H., Kasai K., Tanaka T., and Tanaka N. Role of p38 mitogen-activated protein kinase pathway on renal failure in the infant rat after burn injury. Shock 21 (2004) 535-542
135. Meldrum D.R. Tumor necrosis factor in the heart. Am J Physiol 274 (1998) R577-R595
136. Kan W., Zhao K.S., Jiang Y., Yan W., Huang Q., Wang J., et al. Lung, spleen, and kidney are the major places for inducible nitric oxide synthase expression in endotoxic shock: role of p38 mitogen-activated protein kinase in signal transduction of inducible nitric oxide synthase expression. Shock 21 (2004) 281-287
137. Lub-de Hooge M.N., de Jong S., Vermot-Desroches C., Tulleken J.E., de Vries E.G., and Zijlstra J.G. Endotoxin increases plasma soluble tumor necrosis factor-related apoptosis-inducing ligand level mediated by the p38 mitogen-activated protein kinase signaling pathway. Shock 22 (2004) 186-188
138. Hsieh Y.C., Yang S., Choudhry M.A., Yu H.P., Rue III L.W., Bland K.I., et al. PGC-1 upregulation via estrogen receptors: a common mechanism of salutary effects of estrogen and flutamide on heart function after trauma-hemorrhage. Am J Physiol, Heart Circ Physiol 289 (2005) H2665-H2672
139. Kher A., Wang M., Tsai B.M., Pitcher J.M., Greenbaum E.S., Nagy R.D., et al. Sex differences in the myocardial inflammatory response to acute injury. Shock 23 (2005) 1-10
140. Matsutani T., Anantha Samy T.S., Kang S.C., Bland K.I., and Chaudry I.H. Mouse genetic background influences severity of immune responses following trauma-hemorrhage. Cytokine 30 (2005) 168-176
141. Szalay L., Shimizu T., Schwacha M.G., Choudhry M.A., Rue3rd L.W., Bland K.I., et al. Mechanism of salutary effects of estradiol on organ function after trauma-hemorrhage: upregulation of heme oxygenase. Am J Physiol, Heart Circ Physiol 289 (2005) H92-H98
142. Wang M., Baker L., Tsai B.M., Meldrum K.K., and Meldrum D.R. Sex differences in the myocardial inflammatory response to ischemia-reperfusion injury. Am J Physiol: Endocrinol Metab 288 (2005) E321-E326
143. Yokoyama Y., Nimura Y., Nagino M., Bland K.I., and Chaudry I.H. Current understanding of gender dimorphism in hepatic pathophysiology. J Surg Res 128 (2005) 147-156
144. Yu H.P., Yang S., Choudhry M.A., Hsieh Y.C., Bland K.I., and Chaudry I.H. Mechanism responsible for the salutary effects of flutamide on cardiac performance after trauma-hemorrhagic shock: upregulation of cardiomyocyte estrogen receptors. Surgery 138 (2005) 85-92
145. Ziesche R., Petkov V., Williams J., Zakeri S.M., Mosgoller W., Knofler M., et al. Lipopolysaccharide and interleukin 1 augment the effects of hypoxia and inflammation in human pulmonary arterial tissue. Proc Natl Acad Sci USA 93 (1996) 12478-12483